英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Home - Mesoblast Ltd
    Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care
  • Mesoblast - Wikipedia
    Mesoblast Limited is an Australian regenerative medicine company It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain The company is led by Silviu Itescu, who founded the company in 2004 [1]
  • Mesoblast finally pushes GvHD cell therapy over finish line
    Mesoblast has secured FDA approval for the first-ever mesenchymal stem cell (MSC) therapy, Ryoncil for acute GvHD in children undergoing HSCT
  • Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway . . .
    Mesoblast Limited NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update
  • After two rejections, FDA approves Mesoblasts GVHD cell therapy
    After two rejections from the FDA, Mesoblast has finally gained approval for its first drug, Ryoncil, a cell therapy for graft versus host disease
  • FDA Fast-Tracks Mesoblast Heart Failure Drug While Ryoncil Launch . . .
    About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications These granted patents and patent applications are expected to provide
  • Mesoblast Maintains Momentum with FDA | Mesoblast
    Mesoblast Maintains Momentum with FDA June 12, 2025 at 10:14 AM AEST 569bc968-38c7-405f-baa8-1914745945fc pdf 259 2 KB Investor Relations At A Glance Overview; Corporate Governance; Board of Directors; Management Team; Company Announcements ASX Announcements; Share Price Tools Stock Quote Chart; Historical Lookup;
  • FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatment
    Mesoblast has gained US Food and Drug Administration (FDA) approval for its mesenchymal stromal cell (MSC) therapy, Ryoncil (remestemcel-L), to treat steroid-refractory acute graft versus host disease (SR-aGvHD) in paediatric patients aged a minimum of two months and up to adolescents and teenagers
  • Mesoblast Moves Closer To FDA Approvals For Heart And Immune . . . - Nasdaq
    (RTTNews) - Mesoblast (MESO, MSB AX) has shared an update about its progress with the U S Food and Drug Administration The company is working toward faster approval for its heart failure
  • Overview - Mesoblast Ltd
    Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions





中文字典-英文字典  2005-2009